Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%

Genocea Biosciences Inc (NASDAQ:GNCA) saw a significant increase in short interest in January. As of January 31st, there was short interest totalling 2,870,612 shares, an increase of 73.9% from the January 12th total of 1,651,170 shares. Based on an average trading volume of 1,916,972 shares, the short-interest ratio is currently 1.5 days. Approximately 6.7% of the shares of the stock are short sold.

Shares of Genocea Biosciences (NASDAQ GNCA) traded down $0.05 during trading hours on Friday, reaching $0.93. 1,765,376 shares of the company traded hands, compared to its average volume of 1,300,435. The stock has a market capitalization of $76.32, a PE ratio of -0.43 and a beta of 1.55. Genocea Biosciences has a 12 month low of $0.79 and a 12 month high of $7.29. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51.

Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Monday, October 16th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Genocea Biosciences in a research note on Thursday, November 2nd. Finally, Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $4.45.

A number of large investors have recently modified their holdings of the stock. Ameriprise Financial Inc. grew its stake in Genocea Biosciences by 11.5% during the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 2,300 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $100,000. Rhumbline Advisers purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $157,000. New York State Common Retirement Fund purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $159,000. Finally, OxFORD Asset Management LLP purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $204,000. 12.02% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/short-interest-in-genocea-biosciences-inc-gnca-grows-by-73-9.html.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply